Feedback | Saturday, June 15, 2024

June 3, 2024 2:52 PM

GSK blood cancer drug nearly halves risk of death in late-stage trial

GSK's GSK.L multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday. In the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% of those who received Blenrep in combination with the steroid dexamethasone and pomalidomide were alive without their disease worsening at the end of a year. ...

Copyright © 2024 DD News. All rights reserved
Visitors: 3610362
Last Updated: 15th Jun 2024